Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

A comparison between accelerated hypofractionation and stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer (NSCLC): Results of a propensity score-matched analysis.

Chiang A, Thibault I, Warner A, Rodrigues G, Palma D, Soliman H, Jain S, Poon I, Cheung P.

Radiother Oncol. 2016 Mar;118(3):478-84. doi: 10.1016/j.radonc.2015.12.026. Epub 2016 Jan 18.

PMID:
26795773
2.

Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly.

Shirvani SM, Jiang J, Chang JY, Welsh JW, Gomez DR, Swisher S, Buchholz TA, Smith BD.

Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1060-70. doi: 10.1016/j.ijrobp.2012.07.2354. Epub 2012 Sep 11.

3.

Survival and quality of life after stereotactic or 3D-conformal radiotherapy for inoperable early-stage lung cancer.

Widder J, Postmus D, Ubbels JF, Wiegman EM, Langendijk JA.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e291-7. doi: 10.1016/j.ijrobp.2011.03.052. Epub 2011 Jun 2.

PMID:
21640503
4.

Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer.

Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF, Senan S.

Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):348-53. doi: 10.1016/j.ijrobp.2011.06.2003. Epub 2011 Nov 19.

PMID:
22104360
5.

Stereotactic Ablative Radiotherapy for stage I histologically proven non-small cell lung cancer: an Italian multicenter observational study.

Ricardi U, Frezza G, Filippi AR, Badellino S, Levis M, Navarria P, Salvi F, Marcenaro M, Trovò M, Guarneri A, Corvò R, Scorsetti M.

Lung Cancer. 2014 Jun;84(3):248-53. doi: 10.1016/j.lungcan.2014.02.015. Epub 2014 Mar 13.

6.

Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.

Senthi S, Lagerwaard FJ, Haasbeek CJ, Slotman BJ, Senan S.

Lancet Oncol. 2012 Aug;13(8):802-9. doi: 10.1016/S1470-2045(12)70242-5. Epub 2012 Jun 22.

PMID:
22727222
7.

Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.

Bollineni VR, Widder J, Pruim J, Langendijk JA, Wiegman EM.

Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):e551-5. doi: 10.1016/j.ijrobp.2012.01.012. Epub 2012 Mar 13.

PMID:
22417800
8.

Stage I-II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis.

Verstegen NE, Oosterhuis JW, Palma DA, Rodrigues G, Lagerwaard FJ, van der Elst A, Mollema R, van Tets WF, Warner A, Joosten JJ, Amir MI, Haasbeek CJ, Smit EF, Slotman BJ, Senan S.

Ann Oncol. 2013 Jun;24(6):1543-8. doi: 10.1093/annonc/mdt026. Epub 2013 Feb 20. Erratum in: Ann Oncol. 2013 Sep;24(9):2466.

PMID:
23425947
9.

Is radiofrequency ablation more effective than stereotactic ablative radiotherapy in patients with early stage medically inoperable non-small cell lung cancer?

Bilal H, Mahmood S, Rajashanker B, Shah R.

Interact Cardiovasc Thorac Surg. 2012 Aug;15(2):258-65. doi: 10.1093/icvts/ivs179. Epub 2012 May 10. Review.

10.

Comparison of clinical outcome of stage I non-small cell lung cancer treated surgically or with stereotactic radiotherapy: results from propensity score analysis.

Mokhles S, Verstegen N, Maat AP, Birim Ö, Bogers AJ, Mokhles MM, Lagerwaard FJ, Senan S, Takkenberg JJ.

Lung Cancer. 2015 Mar;87(3):283-9. doi: 10.1016/j.lungcan.2015.01.005. Epub 2015 Jan 15.

PMID:
25622781
11.

The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.

Stahl JM, Ross R, Harder EM, Mancini BR, Soulos PR, Finkelstein SE, Shafman TD, Dosoretz AP, Evans SB, Husain ZA, Yu JB, Gross CP, Decker RH.

Int J Radiat Oncol Biol Phys. 2016 Dec 1;96(5):1011-1020. doi: 10.1016/j.ijrobp.2016.08.033. Epub 2016 Aug 31.

PMID:
27869080
12.

Comparison of accelerated hypofractionation and stereotactic body radiotherapy for Stage 1 and node negative Stage 2 non-small cell lung cancer (NSCLC).

Lucas JT Jr, Kuremsky JG, Soike M, Hinson WW, Kearns WT, Hampton CJ, Blackstock AW, Urbanic J.

Lung Cancer. 2014 Jul;85(1):59-65. doi: 10.1016/j.lungcan.2014.04.003. Epub 2014 Apr 28.

PMID:
24813936
13.

Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial.

Sun B, Brooks ED, Komaki R, Liao Z, Jeter M, McAleer M, Balter PA, Welsh JD, O'Reilly M, Gomez D, Hahn SM, Sepesi B, Rice DC, Heymach JV, Chang JY.

J Thorac Oncol. 2017 Jun;12(6):983-992. doi: 10.1016/j.jtho.2017.02.018. Epub 2017 Mar 1.

14.

Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; systematic review and comparison with a surgical cohort.

Soldà F, Lodge M, Ashley S, Whitington A, Goldstraw P, Brada M.

Radiother Oncol. 2013 Oct;109(1):1-7. doi: 10.1016/j.radonc.2013.09.006. Epub 2013 Oct 12. Review.

15.

Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly.

Shirvani SM, Jiang J, Chang JY, Welsh J, Likhacheva A, Buchholz TA, Swisher SG, Smith BD.

JAMA Surg. 2014 Dec;149(12):1244-53. doi: 10.1001/jamasurg.2014.556.

16.

7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.

Sun B, Brooks ED, Komaki RU, Liao Z, Jeter MD, McAleer MF, Allen PK, Balter PA, Welsh JD, O'Reilly MS, Gomez D, Hahn SM, Roth JA, Mehran RJ, Heymach JV, Chang JY.

Cancer. 2017 Aug 15;123(16):3031-3039. doi: 10.1002/cncr.30693. Epub 2017 Mar 27.

17.

Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer.

Chang JY, Liu H, Balter P, Komaki R, Liao Z, Welsh J, Mehran RJ, Roth JA, Swisher SG.

Radiat Oncol. 2012 Sep 10;7:152.

18.

Multi-Institutional Experience of Stereotactic Ablative Radiation Therapy for Stage I Small Cell Lung Cancer.

Verma V, Simone CB 2nd, Allen PK, Gajjar SR, Shah C, Zhen W, Harkenrider MM, Hallemeier CL, Jabbour SK, Matthiesen CL, Braunstein SE, Lee P, Dilling TJ, Allen BG, Nichols EM, Attia A, Zeng J, Biswas T, Paximadis P, Wang F, Walker JM, Stahl JM, Daly ME, Decker RH, Hales RK, Willers H, Videtic GM, Mehta MP, Lin SH.

Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):362-371. doi: 10.1016/j.ijrobp.2016.10.041. Epub 2016 Nov 2.

PMID:
28011047
19.

Is stereotactic ablative radiotherapy equivalent to sublobar resection in high-risk surgical patients with stage I non-small-cell lung cancer?

Mahmood S, Bilal H, Faivre-Finn C, Shah R.

Interact Cardiovasc Thorac Surg. 2013 Nov;17(5):845-53. doi: 10.1093/icvts/ivt262. Epub 2013 Jul 30. Review.

20.

Stereotactic ablative body radiation therapy for octogenarians with non-small cell lung cancer.

Takeda A, Sanuki N, Eriguchi T, Kaneko T, Morita S, Handa H, Aoki Y, Oku Y, Kunieda E.

Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):257-63. doi: 10.1016/j.ijrobp.2013.01.006. Epub 2013 Apr 6.

PMID:
23570699

Supplemental Content

Support Center